Thursday, February 05, 2015 1:27:21 PM
MARLBOROUGH, Mass., Feb. 5, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies addressing high-unmet medical needs, today announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone™ with Hapten Pharmaceuticals, LLC.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Under the terms of the license agreement, Hapten received a one-time upfront cash payment of $100,000 and 200,000 shares of RXi common stock. Hapten will also be entitled to receive future milestone payments tied to the achievement of certain clinical and commercial objectives, such as the enrollment of the first patient in a Phase 3 clinical trial and regulatory approval, and escalating royalties based on product sales.
About Samcyprone™
Samcyprone™, a proprietary immunomodulating topical gel containing the active agent diphenylcyclopropenone (DPCP), is currently in Phase 2a clinical trials for the treatment of alopecia areata, warts and cutaneous metastases of malignant melanoma. The proprietary gel formulation of DPCP, developed by Hapten Pharmaceuticals, LLC, should provide an improvement in the overall safety and tolerability profile compared to treatment with DPCP as currently used. Typically, patients treated with DPCP are initially sensitized with a single high concentration of drug and subsequently treated with low non-irritant concentrations. Use of high concentrations of DPCP during the sensitization dose results in hyper-sensitizing the patient to subsequent challenge doses. In contrast, the use of Samcyprone™ results in sensitization using a much lower concentration of DPCP, avoiding hyper-sensitization to challenge doses, which should result in an improved safety and tolerability profile while maintaining the known efficacy of DPCP.
Additional information on Samcyprone™ is available and may be found on the "Technology" section of the Company's website, www.rxipharma.com.
About Hapten Pharmaceuticals, LLC
Hapten Pharmaceuticals, LLC is an early stage dermatology product development company based in New York, NY. Hapten's Samcyprone™ is a topical immunomodulator that incorporates DPCP in a proprietary gel formulation.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the area of dermatology and ophthalmology, addressing high-unmet medical needs. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and retinal scarring. It also includes an immunomodulator, Samcyprone™, a proprietary gel formulation of diphenylcyclopropenone (DPCP), for the treatment of such disorders as alopecia areata, warts, and cutaneous metastases of melanoma.
RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations and planned and future development of RXi Pharmaceuticals Corporation's products, technologies and partnerships. Forward-looking statements about expectations and development plans of RXi's products and partnerships involve significant risks and uncertainties such as: the risk that we may not be able to successfully develop and commercialize the Samcyprone™ product candidates, or that development of the Samcyprone™ product candidates may be delayed or not proceed as planned, risks related to the development and commercialization of products by our competitors, the risk related to our ability to control the timing and terms of collaborations with third parties and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
SOURCE RXi Pharmaceuticals Corporation
RELATED LINKS
http://www.rxipharma.com
More by this Source
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Ocular Indications
Feb 03, 2015, 07:02 ET
RXi Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
Feb 02, 2015, 07:02 ET
RXi Pharmaceuticals to Present at the 7th Annual Biotech Showcase™
Jan 05, 2015, 07:02 ET
View all news by RXi Pharmaceuticals Corporation
Recent PHIO News
- Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO) • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells • GlobeNewswire Inc. • 04/22/2024 05:10:09 PM
- Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) • GlobeNewswire Inc. • 04/16/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- National Spotlight Features Phio’s Innovative RNAi Technology Platform • GlobeNewswire Inc. • 04/03/2024 11:30:00 AM
- Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies • GlobeNewswire Inc. • 03/21/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research • GlobeNewswire Inc. • 03/13/2024 06:00:25 PM
- Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders • GlobeNewswire Inc. • 03/06/2024 03:30:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 12:03:51 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:30:10 PM
- Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 10:00:16 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/28/2023 02:13:20 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/28/2023 05:15:20 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/19/2023 09:52:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 10:00:32 PM
- Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:07 PM
- Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/09/2023 09:30:20 PM
- Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas • GlobeNewswire Inc. • 11/09/2023 12:30:00 PM
- Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM